NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Whitehawk Therapeutics, Inc. WHWK
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$7.1M
▼ 72.5% vs FY2024
EPS · FY25
$-0.33
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-21.8%
Net margin · FY25
-288.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 7.1M
Revenue, FY2025 · full 18-year series below
Revenue
Net income
The company lost 288 cents on every revenue dollar this year.
Per share
USD -0.33
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-21.8%
Return on equity, FY2025
ROE
Operating margin-1601.1%
Net margin-288.3%
Return on assets-18.6%
Each USD of equity lost 22 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−12.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−22.3%
−12.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years+0.0%
Change, 10 years—
The share count grew 0% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 150.8M
total assets, end of FY2025
Total assetsUSD 150.8M
EquityUSD 136.3M
CashUSD 37.6M
Current ratio10.26×
Equity funds 90% of total assets.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
·
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.33
−2.36
−2.44
−2.69
−12.41
−1.76
−0.57
−0.31
−1.03
−24.52
−0.01
−0.01
−0.01
−0.01
−0.01
0.00
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
−0
−4
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−21.8
−80.8
−49.9
−41.1
−177.6
·
−93.9
−27.3
·
·
·
·
·
·
·
·
·
−2401.6
Shares out B
0.05
0.02
0.02
0.02
0.02
0.00
0.04
0.04
0.03
0.00
0.01
0.01
0.01
0.01
0.01
0.01
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
39 of 39
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed